[1] Shariff MI,Cox IJ,Gomaa AI,et a1.Hepatocellular carcinoma:current trends in worldwide epidemiology,risk factors,diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol,2009,3(4):353-367. [2] Yang JD,Roberts LR.Hepatocellular carcinoma:a global view. Nat Rev Gastroenterol Hepatol,2010,7(8):448-458. [3] Yuen MF,Hou JL,Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. Gastroenterol Hepatol,2009,24(3):346-353. [4] Muhammad A,Dhamija M,Vidyarthi G,et a1. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol,2013,5(7):364-371. [5] 中华人民共和国卫生部.原发性肝癌诊疗规范.临床肿瘤学杂志,2011,16(10):929-946. [6] Yang JD,Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am,2010,24(10):899-919. [7] Brechot C,Kremsdorf D,Soussan P,et al.Hepatitis B virus(HBV)related hepatocellular carcinoma(HCC):molecular mechanisms and novel paradigms.Pathol Biol (Paris),2010,58(4):278-287. [8] Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int,2011,31(Suppl 1):117-121. [9] Wong R,Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y),2011,7(1):16-24. [10] Bruix J,Sherman M. Management of hepatocellular carcinoma:an update. Hepatology,2011,53(3):1020-1022. [11] Lok AS,Sterling RK,Everhart JE,et al. HALT-C Trial Group. Des-gammacarboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology,2010,138(2):493-502. [12] Tamura Y,Igarashi M,Kawai H,et al. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci,2010,55(12):3576-3583. [13] Malaguarnera G,Giordano M,Paladina I,et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci,2010,55(10):2744-2755. [14] Marrero JA,Fontana RJ,Barrat A,et a1. Prognosis of hepatocellular carcinoma:comparison of 7 staging systems in an American cohort. Hepatology,2005,41(4):707-716. [15] Hsu CY,Huang YH,Hsia CY,et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume:the Taipei Integrated Scoring System. J Hepatol,2010,53(1):108-117. [16] Forner A,Reig ME. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis,2010,30(1):61-74. [17] Forner A,Llovet JM,Bruix J. Hepatocellular carcinoma. Lancet,2012,379(9822):1245-1255. [18] Nathan H,Schulick RD,Choti MA,et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg,2009,249(5):799-805. [19] 樊嘉,王征.原发性肝癌综合治疗新进展.国际消化病杂志,2013,33(2):73-74. [20] European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines:Management of hepatocellular carcinoma. J Hepatol,2012,56(4):908-943. |